Illumina Multiomics Platform Maps Cancer Samples at 1µm Resolution, Detects 2,000 Transcripts
Illumina’s Connected Multiomics platform helped generate whole-transcriptome spatial datasets of human lymphatic vessels at 1µm resolution and identified over 2,000 unique transcripts per cell in breast cancer progression. Its 5-base sequencing enabled simultaneous genomic and methylation profiling, detecting rhabdoid pediatric kidney tumors missed by genomics-only approaches.
1. Oncology Breakthroughs with Connected Multiomics
Illumina announced that customers leveraging its Connected Multiomics platform are achieving new oncological insights by integrating spatial transcriptomics, epigenomics and proteomics data into streamlined multimodal workflows for precision diagnostics and therapeutic development.
2. Spatial Transcriptomics Achieves High-Resolution Mapping
Its Spatial Technology produced whole-transcriptome datasets at 1µm resolution for lymphatic tissue and breast cancer samples, resolving single-cell-thick layers and mapping over 2,000 transcripts per cell, outperforming competing methods in sensitivity and throughput.
3. 5-Base Sequencing Enables Epigenomic Profiling
The company’s 5-base sequencing solution simultaneously profiles genomic and methylation signals, enabling researchers to detect rhabdoid pediatric kidney tumors missed by genomics-only assays and expanding non-invasive diagnostic potential.
4. Integrated Multiomics for Ovarian Cancer Diagnostics
In ovarian cancer research, combined use of 5-base profiling, protein prep and spatial analysis improved differentiation between benign and malignant adnexal masses, revealing localized tumor biology and supporting more accurate diagnostic frameworks.